CAAA817A12201 ACTion: A phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants with PSMApositive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists, Omaha locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*